MONTREAL and CHARLOTTE, N.C. , Nov. 25, 2024 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today announced that President and CEO, Joe Oliveto , and Chief Commercial Officer, Lorenz Muller , will participate in a fireside chat at the Piper Sandler 36 th  Annual Healthcare

NDA for CARDAMYST™ in PSVT under review by FDA; PDUFA March 27, 2025 MONTREAL and CHARLOTTE, N.C. , Nov. 12, 2024 (GLOBE NEWSWIRE) -- Milestone ® Pharmaceuticals Inc.  (Nasdaq: MIST) today reported financial results for the third quarter ended September 30, 2024 and provided a corporate update.

Learnings from the Field: Managing PSVT and Studying AFib-RVR in the Community Setting Hosted 10 am ET , Tuesday, October 8, 2024 MONTREAL and CHARLOTTE, N.C. , Sept. 24, 2024 (GLOBE NEWSWIRE) -- Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development

MONTREAL and CHARLOTTE, N.C. , Sept. 06, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced its licensing partner, Ji Xing Pharmaceuticals Ltd

MONTREAL and CHARLOTTE, N.C. , Sept. 04, 2024 (GLOBE NEWSWIRE) -- Milestone ®   Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced the appointment of Joseph Papa to its Board of

MONTREAL and CHARLOTTE, N.C. , Sept. 03, 2024 (GLOBE NEWSWIRE) -- Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST) today announced that President and CEO, Joe Oliveto , will participate in the H.C. Wainwright 26 th Annual Global Investment Conference , to take place from September 9-11, 2024 , in

MONTREAL and CHARLOTTE, N.C. , Aug. 26, 2024 (GLOBE NEWSWIRE) -- Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced an upcoming data presentation on etripamil at the

–  NDA for CARDAMYST™ in PSVT accepted by FDA in 2Q 2024; PDUFA in March 2025 –  Cash of $83.3 million as of June 30, 2024 expected to fund operations into 2026 –  Stuart Duty and Andrew Saik Appointed as Independent Board Directors MONTREAL and CHARLOTTE, N.C. , Aug.

MONTREAL and CHARLOTTE, N.C. , July 31, 2024 (GLOBE NEWSWIRE) -- Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST) today announced that President and CEO, Joe Oliveto , will participate in the BTIG Virtual Biotechnology Conference , to take place from August 5-6, 2024 .

– Two New Independent Directors, Stuart Duty and Andrew Saik , Appointed – Third New Independent Director to Be Appointed to Board in Near Term MONTREAL and CHARLOTTE, N.C. , July 15, 2024 (GLOBE NEWSWIRE) -- Milestone ®   Pharmaceuticals Inc. (Nasdaq: MIST) (“Milestone” or the “Company”), a